TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.

von Joseph H Jeong, Ayesha Bhatia, Zsolt Toth, Soohwan Oh, Kyung-Soo Inn, Chun-Peng Liao, Pradip Roy-Burman, Jonathan Melamed, Gerhard A Coetzee, Jae U Jung
Veröffentlicht 2011-01-01